Abstract P6 09 01: In primary, non metastatic breast cancer patients, increased serum levels of RANKL significantly correlate with tumor cell spread to the bone and the occurrence of bone metastasis whereas high levels of its soluble decoy receptor osteoprotegerin predict poor survival
Background: Receptor activator of nuclear factor kappa B ligand (RANKL) is an essential protein for osteoclast regulation and its activity is controlled by its soluble decoy receptor osteoprotegerin (OPG) RANKL has been associated with benign as well as malignant bone disease and there is increasing evidence that RANKL may also directly affect breast cancer (BC) progression and metastasis to the bone. Here we assessed serum concentrations of RANKL and OPG in 509 patients with primary, non metastatic BC and correlated the results with clinical parameters including the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) survival and the risk of developing metastatic disease. Patients and Methods: Patients with first diagnosis of BC between Aug 2006 and Dec 2009 were included in our study. BM sampling was performed before surgery in an adjuvant setting and two BM aspirates were analyzed for DTCs using density centrifugation followed by immunocytochemistry applying the pan cytokeratin antibody A45 B/B3. Blood was collected from each patient and sRANKL and OPG levels in the serum were measured by ELISA (Biomedica, Vienna, Austria) Results: Mean serum values for RANKL and OPG were 0.23+ 0.20 pmol/l and 4.24+ 1.70 pmol/l, respectively. RANKL levels were significantly lower in women above the age of 60 (p Citation Format: Bittner A K, Goebel A, Hoffmann O, Rauner M, Hofbauer LC, Kimmig R, Kasimir Bauer S, Rachner TD. In primary, non metastatic breast cancer patients, increased serum levels of RANKL significantly correlate with tumor cell spread to the bone and the occurrence of bone metastasis whereas high levels of its soluble decoy receptor osteoprotegerin predict poor survival [abstract] In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4 8; San Antonio, TX. Philadelphia (PA) AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6 09 01.
Poster Session Abstracts